Convenient dosing schedule every 12 weeks after 2 starter doses at Weeks 0 and 4.
FOR STELARA® (ustekinumab)
Janssen CarePath helps your patients start and stay on STELARA® that you've prescribed.
A GROWING LEGACY IN THE TREATMENT OF PLAQUE PSORIASIS
STELARA® has been clinically studied for 16 years1†
More than 7100 dermatologists have prescribed STELARA® in the United States1‡§
More than 155,000 patients with moderate to severe plaque psoriasis treated with STELARA® in the United States1║
STELARA® has more than 1,300,000 patient-years since first exposure worldwide1¶
NATIONAL PSORIASIS FOUNDATION®
Recognized STELARA® as a first-line systemic in moderate to severe plaque psoriasis.2**††
*Including UnitedHealthcare®, OptumRx®, Aetna®, Anthem®, Express Scripts®, Cigna®, and CVS Health®; as of June 1st, 2019.
†A phase 1 clinical trial of STELARA® was initiated in 2001 in patients with moderate to severe plaque psoriasis. Phase 3, double-blind, placebo-controlled, multicenter trials PHOENIX 1 and PHOENIX 2 began in 2005 and 2006, respectively.
‡IMS Health-Xponent data. Prescribers who have written at least 1 prescription for STELARA® in the United States from October 2009 to April 2016.
§Reflects usage across all lines of therapy.
║More than 155,000 patients treated with STELARA® in the United States from September 2009 to August 2016. Estimations are based on calculations using product-utilization data collected in the United States for STELARA® to determine patient type, average dose per administration, total number of administrations, and patient persistency rates.
¶Based on worldwide estimated number of patient-years from launch through December 2018 across all indications. Patient-years since first exposure were estimated by calculations using STELARA® distribution date to determine average yearly dose while considering regional estimates of patient compliance to dosing regimen.
Reference: 1. Data on file. Janssen Biotech, Inc.